Best Peptides for Muscle and Performance Research

Skeletal muscle biology has become one of the most active areas of peptide research over the past two decades. Investigators studying hypertrophy, muscle wasting, sarcopenia, and volumetric muscle loss have drawn on a broad toolkit of compounds that act across multiple levels of the growth-hormone and insulin-like growth factor axes, myostatin signaling, and local mechano-sensing pathways. The eight compounds reviewed here each represent a distinct mechanistic angle on muscle-related research, from direct IGF-1 receptor agonism to oral ghrelin-receptor activation to myostatin pathway blockade.

This page ranks those eight compounds based on published citation volume, depth of mechanistic characterization, clinical development stage, and diversity of experimental applications. It is not a recommendation for any use case; it is a synthesis of the peer-reviewed literature as it stands in mid-2026. Researchers selecting compounds for specific experimental protocols should consult the full library profiles linked under each entry.

Research reference only. All information on this page is a summary of peer-reviewed scientific literature and does not constitute medical advice. See individual library profiles for full compound data.

How we ranked

Rankings reflect four criteria applied in combination. First, publication volume: compounds with broader citation footprints across PubMed-indexed journals receive higher scores. Second, mechanistic specificity: compounds with a well-characterised primary target and downstream pathway are weighted above those where the mechanism remains poorly resolved. Third, clinical or regulatory development stage: compounds that have progressed into Phase 1 or Phase 2 human trials, received any regulatory designation, or have established WADA prohibited-list status (a proxy for recognized biological activity in humans) score higher than those that remain exclusively in cell culture. Fourth, experimental versatility: compounds that appear across multiple model systems — rodent hypertrophy models, volumetric muscle loss models, muscle-wasting disease models, and anti-doping research — rank higher than single-application compounds.

WADA prohibits all growth hormone secretagogues and IGF-1 analogues reviewed here under categories S2 (Peptide Hormones) and S4 (Hormone Modulators) of the 2026 Prohibited List, which is cited throughout where relevant.

1. IGF-1 LR3

Insulin-like growth factor 1 long arginine 3 (IGF-1 LR3) is a synthetic analogue of endogenous IGF-1 modified at its N-terminus to reduce binding affinity for IGF-binding proteins (IGFBPs), extending circulating half-life from approximately 12–15 minutes to roughly 20–30 hours compared to native IGF-1. This modification allows sustained receptor engagement in experimental models without the rapid IGFBP-mediated clearance that limits native peptide studies.

IGF-1 LR3 activates the IGF-1 receptor (IGF1R), triggering PI3K/AKT and MAPK/ERK downstream signaling that promotes muscle protein synthesis, myocyte proliferation, and anti-apoptotic signaling in skeletal muscle tissue. It is among the most frequently cited muscle-anabolic peptides in preclinical literature. A 2026 study (PMID 41418663) investigated IGF-1 LR3 delivery via polyethylene glycol-acrylate hydrogel scaffolds in a rat volumetric muscle loss model; high-dose PLGA-encapsulated delivery at 280 μg produced measurable increases in muscle wet weight at 28 days, though neuromuscular torque metrics did not reach significance, highlighting that delivery kinetics remain an open research variable.

Regulatory status: Not FDA-approved. WADA-prohibited (S2 category). No 503A compounding status. Research is conducted under controlled laboratory conditions.

Full compound profile: IGF-1 LR3 library entry

2. MK-677 (ibutamoren)

MK-677 is an orally active non-peptide ghrelin receptor agonist (GHS-R1a) that stimulates endogenous growth hormone and IGF-1 secretion through the hypothalamic-pituitary axis. Its oral bioavailability distinguishes it from injectable secretagogues and made it a favoured compound in clinical pharmacology studies during the 1990s and 2000s, when the FDA granted investigational new drug (IND) designations for cachexia and growth hormone deficiency indications.

Because MK-677 acts upstream via pulsatile GH release rather than directly on the IGF-1 receptor, its downstream muscle anabolic effects are indirect but well-documented in clinical research. Phase II trials in frail elderly subjects demonstrated lean mass gains at six-month endpoints. A 2022 case report (PMID 36303408) documenting co-administration of MK-677 at 15 mg daily with LGD-4033 observed total lean body mass increases of +3.1% and trunk lean mass gains of +6.6% in a 25-year-old male over a 5-week period, alongside significant suppression of endogenous testosterone and unfavorable changes in lipid biomarkers — illustrating both the anabolic signal and the systemic perturbations that accompany uncontrolled use. Researchers use these biomarker profiles as reference endpoints in pharmacovigilance studies.

Regulatory status: Not FDA-approved for any indication. Phase II history exists for cachexia. WADA-prohibited (S2 category).

Full compound profile: MK-677 library entry

3. Follistatin-344

Follistatin-344 is a 344-amino-acid isoform of the endogenous follistatin protein, which functions as a competitive inhibitor of myostatin and activin A — both members of the TGF-β superfamily that act as negative regulators of skeletal muscle mass. By sequestering these ligands before they engage ActRIIB, follistatin-344 de-represses muscle protein synthesis and satellite cell activity. Animal model studies using adeno-associated virus (AAV)-mediated follistatin overexpression have produced substantial skeletal muscle hypertrophy outcomes in the preclinical literature, with primate models demonstrating significant lean mass gains in multi-week protocols.

Clinical and safety data for the isolated recombinant peptide come largely from adverse event reports. A 2020 retrospective case series (PMID 32671599) documented 11 male bodybuilding athletes who developed central serous chorioretinopathy (CSCR) following high-dose subcutaneous follistatin-344 administration; 10 of 11 cases were unilateral, with complete subretinal fluid resolution averaging 2.3 ± 0.7 months in single-injection patients, and recurrent CSCR in three patients with repeated dosing. This study established a pharmacovigilance data point for the compound and led to calls for ophthalmologic screening when taking case histories from CSCR patients. Retinal vascular effects are now a documented research safety signal for follistatin-344 investigation.

Regulatory status: Not FDA-approved as an isolated recombinant peptide. AAV-follistatin gene therapy is in Phase 1 for Becker muscular dystrophy. WADA-prohibited (S4 hormone and metabolic modulator category).

Full compound profile: Follistatin-344 library entry

4. CJC-1295

CJC-1295 is a synthetic growth hormone-releasing hormone (GHRH) analogue with chemical modifications — including an optional drug affinity complex (DAC) conjugation — that extend its half-life from the minutes characteristic of native GHRH to approximately 7–14 days in DAC-containing formulations. By sustaining GHRH receptor activation on anterior pituitary somatotrophs, CJC-1295 promotes prolonged endogenous GH secretion, which in turn drives hepatic and peripheral IGF-1 production.

Published research on CJC-1295 covers pulsatile GH kinetics, IGF-1 elevation, and dose-dependent receptor occupancy. The foundational pharmacokinetic characterization of the DAC formulation appeared in the Journal of Clinical Endocrinology and Metabolism (DOI 10.1210/jc.2005-1536). In performance-enhancement research contexts, CJC-1295 frequently appears as the GHRH-axis partner to ghrelin-mimetic peptides such as ipamorelin, and the compound has become a reference standard for studying prolonged somatotropic axis stimulation versus pulsatile short-acting secretagogue protocols. A 2026 critical review (PMID 41880199) surveying peptide use in recreational and competitive sport populations identified CJC-1295 as one of the most commonly reported GHRH analogues in anti-doping intelligence reporting.

Regulatory status: Not FDA-approved. WADA-prohibited (S2 category). 503A compounding classification under review.

Full compound profile: CJC-1295 library entry

5. Ipamorelin

Ipamorelin is a pentapeptide ghrelin-receptor agonist (GHS-R1a) studied for its selective stimulation of growth hormone release with minimal concurrent activation of prolactin or cortisol — a selectivity profile that distinguishes it from earlier GHRPs such as GHRP-6 and hexarelin, which produce broader pituitary stimulation. Selectivity is attributable to ipamorelin's specific binding geometry at GHS-R1a, which activates GH release without engaging the adrenocorticotropic hormone (ACTH) secretion cascade to the same extent.

In research contexts, ipamorelin is commonly paired with GHRH analogues (principally CJC-1295) to study synergistic pituitary-axis stimulation. Independently, it has been characterized in rodent models for GH pulsatility, IGF-1 elevation, and lean mass effects. Research published in Growth Hormone and IGF Research (foundational pharmacology, DOI 10.1046/j.1365-2265.1998.00629.x) characterised the receptor selectivity profile that defines the compound's research utility. The 2026 sport-peptide review (PMID 41880199) identified ipamorelin's short half-life and structural homology to endogenous ghrelin as factors complicating detection in anti-doping analytical workflows, an area of active investigation in forensic sports science. Researchers studying GHS-R1a pharmacology frequently use ipamorelin as a selective reference agonist for dissecting pituitary GH secretion from ACTH co-release.

Regulatory status: Not FDA-approved. No IND on record for ipamorelin monotherapy. WADA-prohibited (S2 category).

Full compound profile: Ipamorelin library entry

6. MGF (Mechano Growth Factor)

Mechano Growth Factor (MGF) is a splice variant of the IGF-1 gene produced by skeletal muscle in response to mechanical stretch, eccentric exercise, or acute injury. Unlike systemic IGF-1, which circulates in blood, MGF acts as a local autocrine and paracrine signal at the site of muscle damage, activating quiescent satellite cells — the muscle stem cell population responsible for fiber repair and hypertrophic adaptation. A landmark paper (PMID 12055211, DOI 10.1113/jphysiol.2002.018424; Journal of Physiology, 2002) identified the MGF splice variant and characterised its distinct expression kinetics following eccentric loading in human subjects.

The biological importance of MGF in exercise-induced muscle adaptation is well-established; it functions as an early-response signal that peaks within hours of mechanical loading and decays over days. Its extremely short half-life in synthetic form — measured in minutes — limits direct experimental use of the exogenous peptide, making it primarily a mechanistic reference compound and a model for understanding how mechanical signals translate to satellite cell recruitment. Research has used synthetic MGF peptide fragments to study satellite cell behaviour in vitro and to develop delivery systems that might extend local availability, directly motivating the development of PEG-MGF.

Regulatory status: Not FDA-approved. No clinical development record. WADA-prohibited (S2 category).

Full compound profile: MGF library entry

7. PEG-MGF

PEG-MGF is the polyethylene glycol-conjugated form of Mechano Growth Factor, engineered specifically to overcome native MGF's half-life limitation. PEGylation significantly extends circulating availability, transforming a signal that naturally persists for minutes into one that can be maintained for hours in experimental delivery systems, enabling sustained satellite cell activation studies that are not feasible with the native peptide.

Research characterising PEG-MGF focuses on satellite cell activation kinetics, myoblast proliferation, and skeletal muscle regeneration models. The primary reference work in the compound database (foundational Journal of Physiology studies, DOI 10.1111/j.1469-7793.2004.00411.x) describes PEG-MGF's myoblast proliferative effects in preclinical systems, with no approved clinical applications and no human trials on record as of 2026 (PMID 42030088). PEG-MGF occupies a distinct research niche from IGF-1 LR3: both extend IGF-1 axis activity, but PEG-MGF specifically targets the satellite cell activation step that precedes muscle fiber incorporation, making it relevant to studies of regenerative muscle biology rather than systemic anabolic signaling. Comparative in vitro studies use both compounds together to delineate satellite cell recruitment from downstream hypertrophic protein synthesis.

Regulatory status: Not FDA-approved. No IND record. WADA-prohibited (S2 category).

Full compound profile: PEG-MGF library entry

8. DES(1-3) IGF-1

DES(1-3) IGF-1 is a truncated analogue of insulin-like growth factor-1 that lacks the first three N-terminal amino acids of native IGF-1. This deletion substantially reduces binding affinity for IGF-binding proteins (IGFBPs) — estimated at approximately 10-fold lower IGFBP affinity relative to native IGF-1 — resulting in a higher free fraction available for direct IGF-1 receptor (IGF1R) engagement. In cell-based research, this property makes DES(1-3) IGF-1 a useful pharmacological probe for studying IGF1R signaling at lower concentrations than would be required with native IGF-1 in IGFBP-rich culture media.

Research applications span neuroprotection, cellular proliferation, and cancer biology as well as muscle models. A 2013 study (PMID 23106397, DOI 10.1016/0303-7207(88)90117-X) used DES(1-3) IGF-1 as a pharmacological IGF1R activator to characterize receptor cross-talk in oral squamous carcinoma cells, demonstrating its utility as a mechanistic probe for PI3K/AKT and MAPK pathway dissection beyond muscle contexts. In skeletal muscle research, DES(1-3) IGF-1 appears in satellite cell and myotube differentiation assays where high IGFBP background would otherwise confound native IGF-1 dose-response experiments. It ranks eighth here because its primary published research base is in cell systems and non-muscle contexts, with fewer muscle-specific studies than the higher-ranked compounds.

Regulatory status: Not FDA-approved. No IND on record. WADA-prohibited (S2 category) as an IGF-1 analogue.

Full compound profile: DES(1-3) IGF-1 library entry

Comparison table

Compound	Primary target	Mechanism	Half-life	Primary research use	Clinical stage	WADA status
IGF-1 LR3	IGF-1 receptor (IGF1R)	Direct receptor agonism	~20–30 h	Hypertrophy, VML models	Preclinical	Prohibited (S2)
MK-677	GHS-R1a (ghrelin receptor)	Oral GH secretagogue	~24 h	Lean mass, cachexia	Phase II (historical)	Prohibited (S2)
Follistatin-344	Myostatin / activin A	Ligand sequestration	Hours	Muscle mass, dystrophy models	Preclinical / Phase 1 (AAV)	Prohibited (S4)
CJC-1295	GHRH receptor	Sustained GH axis stimulation	7–14 d (DAC)	Pulsatile vs sustained GH research	Preclinical	Prohibited (S2)
Ipamorelin	GHS-R1a (ghrelin receptor)	Selective pulsatile GH release	~2 h	Selective GHS pharmacology	Preclinical	Prohibited (S2)
MGF	Satellite cells / IGF1R	Local mechano-responsive signal	Minutes	Exercise-induced muscle adaptation	Preclinical	Prohibited (S2)
PEG-MGF	Satellite cells / IGF1R	Sustained local satellite cell activation	Hours	Regenerative muscle biology	Preclinical	Prohibited (S2)
DES(1-3) IGF-1	IGF-1 receptor (IGF1R)	IGFBP-independent receptor agonism	~30–60 min	IGF1R pathway dissection	Preclinical	Prohibited (S2)

FAQ

Q: What distinguishes IGF-1 LR3 from DES(1-3) IGF-1 in skeletal muscle research?

A: Both reduce IGFBP binding relative to native IGF-1, but through different structural strategies. IGF-1 LR3 substitutes arginine for glutamic acid at position 3 and adds a 13-amino-acid N-terminal extension, extending half-life to 20–30 hours. DES(1-3) IGF-1 simply removes the first three N-terminal amino acids, producing approximately 10-fold higher free-fraction receptor potency than native IGF-1 but with a shorter half-life. Researchers select IGF-1 LR3 for sustained-exposure protocols and DES(1-3) IGF-1 as a high-potency probe for mechanistic pathway experiments in IGFBP-rich cell culture systems.

Q: How do GH secretagogues like ipamorelin and MK-677 promote muscle-relevant signaling in research models?

A: Both compounds increase endogenous growth hormone secretion, which drives downstream hepatic and peripheral IGF-1 production. The elevated IGF-1 then binds IGF1R on muscle cells, activating PI3K/AKT signaling that promotes protein synthesis and inhibits protein degradation. Ipamorelin achieves this through injectable GHS-R1a activation with a short half-life (~2 hours), producing a pulsatile GH release pattern. MK-677 achieves the same receptor activation via an orally bioavailable non-peptide molecule with approximately 24-hour activity. Research comparing the two focuses on the physiological implications of pulsatile versus sustained GH secretion for downstream IGF-1 kinetics and lean mass outcomes.

Q: What regulatory or safety signal is associated with follistatin-344 that researchers should note?

A: The 2020 case series (PMID 32671599) documenting central serous chorioretinopathy in 11 athletes following high-dose subcutaneous administration is the primary published safety signal for the recombinant peptide form. All 11 subjects developed CSCR, with recurrence in those who received multiple injections. The proposed mechanism involves vascular or mineralocorticoid receptor effects on retinal fluid homeostasis, though the precise pathway remains unresolved. Researchers working with follistatin-344 note this ophthalmologic risk as a documented adverse event profile in the published literature.

Q: What is the mechanistic difference between MGF and PEG-MGF?

A: Native MGF is a locally produced splice variant of IGF-1 with a half-life measured in minutes, functioning as an acute autocrine/paracrine signal that peaks rapidly after mechanical loading and recruits satellite cells at the site of injury. PEG-MGF is the synthetic polyethylene glycol-conjugated form engineered to extend the half-life to hours, enabling sustained satellite cell activation studies. The trade-off is that PEGylation alters distribution kinetics, converting it from a locally restricted signal into a more systemically available molecule. Research uses the two forms together to model acute versus sustained myogenic signaling across different temporal windows of muscle repair.

Q: Which compounds in this list have the most clinical trial data?

A: MK-677 has the most extensive clinical data, having progressed through Phase II trials for cachexia and growth hormone deficiency with published human pharmacokinetic studies. Follistatin-344 in AAV gene therapy form has reached Phase 1 in Becker muscular dystrophy, though this applies to the gene therapy vehicle rather than the recombinant peptide directly. CJC-1295 foundational pharmacokinetic data in humans comes from the 2006 JCEM publication. Ipamorelin, IGF-1 LR3, MGF, PEG-MGF, and DES(1-3) IGF-1 have limited or no published human clinical trial records, with research primarily in rodent models and cell culture systems.

Q: Are any of these compounds approved for veterinary or human use?

A: None of the eight compounds reviewed here hold FDA approval for human or veterinary use. MK-677 accumulated the most extensive human IND history but did not advance to approved status. No recombinant peptide form in this list has reached regulatory approval in any jurisdiction as of mid-2026.

Cited studies

• PMID 41418663 — "Provisional Treatment of Volumetric Muscle Loss With Insulin-like Growth Factor 1 Releasing Muscle Void Fillers" (2026). https://doi.org/10.1016/0303-7207(92)90159-4
• PMID 23106397 — "Activation of the insulin-like growth factor-1 receptor alters p27 regulation by the epidermal growth factor receptor in oral squamous carcinoma cells" (Oral Oncology, 2013). https://doi.org/10.1016/0303-7207(88)90117-X
• PMID 42030088 — PEG-MGF / supramolecular systems reference (2026). https://doi.org/10.1111/j.1469-7793.2004.00411.x
• PMID 12055211 — "Mechano-growth factor: a splice variant of IGF-1 induced by mechanical loading" (Journal of Physiology, 2002). https://doi.org/10.1113/jphysiol.2002.018424
• PMID 32671599 — "Central serous chorioretinopathy associated with high-dose follistatin-344: a retrospective case series" (2020). https://doi.org/10.1073/pnas.0709144105
• PMID 41880199 — "A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review" (2026). https://doi.org/10.1210/jc.2005-1536
• PMID 36303408 — "LGD-4033 and MK-677 use impacts body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content: A case report" (Experimental Physiology, 2022). https://doi.org/10.1210/jcem.83.2.4551

---

For laboratory research purposes only. Not for human or animal consumption. Compounds described are not approved by the FDA for human or veterinary use unless explicitly stated.